2. Amyotrophic lateral sclerosis
508 clinical trials,   530 drugs   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04569084
(ClinicalTrials.gov)
November 13, 202023/9/2020Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALSA Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)ALSDrug: MT-1186;Drug: PlaceboMitsubishi Tanabe Pharma Development America, Inc.NULLRecruiting18 Years75 YearsAll380Phase 3United States
2NCT04391361
(ClinicalTrials.gov)
November 1, 202013/5/2020The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALSThe Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis;Respiratory Function;ScopolamineDrug: Scopolamine, atropine, edaravone and dexmedetomidine;Drug: EdaravoneRuijin HospitalNULLNot yet recruiting30 Years65 YearsAll30Phase 2China
3NCT04577404
(ClinicalTrials.gov)
October 29, 202030/9/2020Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)Drug: MT-1186Mitsubishi Tanabe Pharma Development America, Inc.NULLRecruiting18 YearsN/AAll140Phase 3United States
4EUCTR2019-002108-41-DE
(EUCTR)
06/05/202017/01/2020A Safety Study of Oral Edaravone in Subjects with Amyotrophic Lateral Sclerosis (ALS)A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Edaravone
Product Code: MT-1186
INN or Proposed INN: EDARAVONE
Mitsubishi Tanabe Pharma Development America, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150Phase 3United States;France;Canada;Germany;Japan;Italy
5NCT04254913
(ClinicalTrials.gov)
January 24, 202023/1/2020Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With GastrostomyClinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With GastrostomyJapanese Patients With ALSDrug: MT-1186Mitsubishi Tanabe Pharma CorporationNULLCompleted20 Years80 YearsAll6Phase 1Japan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT04259255
(ClinicalTrials.gov)
October 21, 201927/1/2020Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)Amyotrophic Lateral Sclerosis;ALSDrug: EdaravoneMitsubishi Tanabe Pharma America Inc.Massachusetts General HospitalRecruiting18 YearsN/AAll300United States
7NCT04176224
(ClinicalTrials.gov)
April 17, 201922/11/2019Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral SclerosisClinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)Japanese Patients With ALSDrug: MT-1186Mitsubishi Tanabe Pharma CorporationNULLCompleted20 Years75 YearsAll9Phase 1Japan
8NCT03272802
(ClinicalTrials.gov)
March 16, 20172/9/2017Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) in a Representative Iranian PopulationNeuromuscular DiseasesDrug: Edaravone;Drug: RiluzoleIsfahan University of Medical SciencesNULLActive, not recruiting18 Years75 YearsAll20Phase 2;Phase 3Iran, Islamic Republic of
9JPRN-UMIN000024854
2016/11/1616/11/2016Clinical study of the effectiveness of edaravone for the oxidative stress in amyotrophic lateral sclerosisClinical study of the effectiveness of edaravone for the oxidative stress in amyotrophic lateral sclerosis - Clinical study for the anti-oxidative stress by edaravone in ALS Amyotrophic Lateral Sclerosis (ALS)Edaravone treatment for ALS patientsOkayama universityNULLComplete: follow-up complete20years-old75years-oldMale and Female20Not applicableJapan
10JPRN-UMIN000016352
2015/02/0101/02/2015The Safety of Edaravone for patients with Amyotrophic Lateral Sclerosis: Single centered open label trial amyotrophic lateral sclerosisedaravoneEhime University HospitalNULLComplete: follow-up complete20years-oldNot applicableMale and Female10Phase 1;Phase 2Japan